Ventana's c-Kit test for GISTs:
This article was originally published in Clinica
Executive Summary
The US FDA has approved for sale Ventana Medical Systems' VentanaDx, a diagnostic kit for allowing physicians to detect c-KIT protein in gastrointestinal stromal tumours (GISTs). While not the sole basis for making a diagnosis of GIST, c-KIT can help in the selection of patients who may be eligible for treatment with Novartis' Gleevec (imatinib mesylate), said Tucson, Arizona-based Ventana. GISTs belong to a rare family of tumours known as soft tissue sarcomas, which most often develop in the stomach, but may also affect the small intestine, colon or oesophagus.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.